Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 Levels in patients with dyslipidemia

American Journal of Cardiology

Volumn 115, Issue 2, 2015, Pages 178-182

  Khera, Amit V ^a   Qamar, Arman ^b   Reilly, Muredach P ^b   Dunbar, Richard L ^b   Rader, Daniel J ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KEXIN; KEXIN TYPE 9; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SIMVASTATIN; SUBTILISIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ADULT; ARTICLE; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; AGED; APOPTOSIS; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; DYSLIPIDEMIAS; MULTICENTER STUDY; TREATMENT OUTCOME;

AGED; APOPTOSIS; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MALE; NIACIN; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME;

EID: 84919663233     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.10.018     Document Type: Article

References (20)

1. J.D. Horton, J.C. Cohen, and H.H. Hobbs PCSK9: a convertase that coordinates LDL catabolism J Lipid Res 50 2009 S172 S177
2. E.M. Roth, J.M. McKenney, C. Hanotin, G. Asset, and E.A. Stein Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia N Engl J Med 367 2012 1891 1900
3. F. Raal, R. Scott, R. Somaratne, I. Bridges, G. Li, S.M. Wasserman, and E.A. Stein Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial Circulation 126 2012 2408 2417
4. M.J. Koren, R. Scott, J.B. Kim, B. Knusel, T. Liu, L. Lei, M. Bolognese, and S.M. Wasserman Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study Lancet 380 2012 1995 2006
5. R.P. Giugliano, N.R. Desai, P. Kohli, W.J. Rogers, R. Somaratne, F. Huang, T. Liu, S. Mohanavelu, E.B. Hoffman, S.T. McDonald, T.E. Abrahamsen, S.M. Wasserman, R. Scott, M.S. Sabatine LAPLACE-TIMI 57 Investigators Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study Lancet 380 2012 2007 2017
6. H.E. Careskey, R.A. Davis, W.E. Alborn, J.S. Troutt, G. Cao, and R.J. Konrad Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 J Lipid Res 49 2008 394 398
7. G. Welder, I. Zineh, M.A. Pacanowski, J.S. Troutt, G. Cao, and R.J. Konrad High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol J Lipid Res 51 2010 2714 2721
8. Z. Awan, N.G. Seidah, J.G. MacFadyen, S. Benjannet, D.I. Chasman, P.M. Ridker, and J. Genest Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial Clin Chem 58 2012 183 189
9. G. Lambert, N. Ancellin, F. Charlton, D. Comas, J. Pilot, A. Keech, S. Patel, D.R. Sullivan, J.S. Cohn, K.A. Rye, and P.J. Barter Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment Clin Chem 54 2008 1038 1045
10. J.S. Troutt, W.E. Alborn, G. Cao, and R.J. Konrad Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels J Lipid Res 51 2010 345 351
11. T. Noguchi, J. Kobayashi, K. Yagi, A. Nohara, N. Yamaaki, M. Sugihara, N. Ito, R. Oka, M.A. Kawashiri, H. Tada, M. Takata, A. Inazu, M. Yamagishi, and H. Mabuchi Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study Atherosclerosis 217 2011 165 170
12. B. Ky, A. Burke, S. Tsimikas, M.L. Wolfe, M.G. Tadesse, P.O. Szapary, J.L. Witztum, G.A. FitzGerald, and D.J. Rader The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans J Am Coll Cardiol 51 2008 1653 1662
13. S.L. Airan-Javia, R.L. Wolf, M.L. Wolfe, M. Tadesse, E. Mohler, and M.P. Reilly Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy Am Heart J 157 2009 687.e1 687.e8
14. F. Raal, V. Panz, A. Immelman, and G. Pilcher Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy J Am Heart Assoc 2 2013
15. R.J. Konrad, J.S. Troutt, and G. Cao Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents Lipids Health Dis 10 2011 38
16. V.S. Kamanna, and M.L. Kashyap Mechanism of action of niacin Am J Cardiol 101 2008 20B 26B
17. Clofibrate and niacin in coronary heart disease JAMA 231 1975 360 381
18. AIM-HIGH Investigators W.E. Boden, J.L. Probstfield, T. Anderson, B.R. Chaitman, P. Desvignes-Nickens, K. Koprowicz, R. McBride, K. Teo, and W. Weintraub Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
19. HPS2-THRIVE Collaborative Group M.J. Landray, R. Haynes, J.C. Hopewell, S. Parish, T. Aung, J. Tomson, K. Wallendszus, M. Craig, L. Jiang, R. Collins, and J. Armitage Effects of extended-release niacin with laropiprant in high-risk patients N Engl J Med 371 2014 203 212
20. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, C.N. Bairey Merz, C.B. Blum, R.H. Eckel, A.C. Goldberg, D. Gordon, D. Levy, D.M. Lloyd-Jones, P. McBride, J.S. Schwartz, S.T. Shero, S.C. Smith Jr., K. Watson, and P.W. Wilson 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2889 2934